Low-dose aspirin significantly lowers cardiovascular disease risk but increases the risk of bleeding, according to a review published in the British Journal of Clinical Pharmacology.
Investigators conducted the review because the overall balance between risks and benefits of taking aspirin has been unclear. The team pooled information from analyses of all relevant observational studies and randomized controlled trials.
Use of low-dose aspirin in people without cardiovascular disease was associated with a 17% lower incidence of cardiovascular events (such as non-fatal heart attacks, non-fatal strokes, or cardiovascular-related deaths). Low-dose aspirin use was also associated with a 47% higher risk of gastrointestinal bleeding and a 34% higher risk of intracranial bleeding.
"These risks and benefits need to be weighted in formal decision analyses to guide aspirin use in primary prevention," said co-author Lee Smith, MSc, PhD, of Anglia Ruskin University, in the UK.
The authors noted that although many dozens of health effects besides cardiovascular disease and bleeding have been assessed, evidence for these remains weak and therefore should not be a major consideration when deciding whether to use low-dose aspirin.
Reference: Veronese, et al. (2020) Effect of low‐dose aspirin on health outcomes: An umbrella review of systematic reviews and meta‐analyses. British Journal of Clinical Pharmacology. DOI: https://doi.org/10.1111/bcp.14310
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.